This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Linderholm, B. Articles by Henriksson, R. Search for Related Content PubMed PubMed Citation Articles by Linderholm, B. Articles by Henriksson, R.

Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment

From the Departments of Oncology and Clinical Chemistry, Umeå University, Umeå, Sweden.

Address reprint requests to Barbro Linderholm, MD, Department of Oncology, Umeå University, SE-901 85 Umeå, Sweden; email barbro.linderholm{at}onkologi.umu.se

PURPOSE: To determine the predictive value of vascular endothelial growth factor (VEGF) for relapse-free survival (RFS) and overall survival (OS) in primary node-positive breast cancer (NPBC) after adjuvant endocrine treatment or adjuvant chemotherapy.

MATERIALS AND METHODS: VEGF was quantitatively measured in tumor cytosols from 362 consecutive patients with primary NPBC using an enzyme immunoassay for human VEGF₁₆₅. Adjuvant treatment was given to all patients, either as endocrine therapy (n = 250) or chemotherapy (n = 112). The median follow-up time was 56 months.

RESULTS: Univariate analysis showed VEGF to be a significant predictor of RFS (P = .0289) and OS (P = .0004) in the total patient population and in patients who received adjuvant endocrine treatment (RFS, P = .0238; OS, P = .0121). In the group of patients who received adjuvant chemotherapy, no significant difference was seen in RFS, but a difference was seen in OS (P = .0235). Patients with bone recurrences tended to have lower VEGF expression (median, 2.17 pg/µg DNA) than patients with visceral metastasis (4.41 pg/µg), brain metastasis (8.29 pg/µg), or soft tissue recurrences (3.16 pg/µg). Multivariate analysis showed nodal status (P = .0004), estrogen receptor (ER) status (P < .0001), and tumor size (P = .0085) to be independent predictors of RFS. VEGF was found to be an independent predictor of OS (P = .0170; relative risk [RR] = 1.82), as were ER (P < .0001; RR = 5.19) and nodal status (P = .0002; RR = 2.58). For patients receiving adjuvant endocrine treatment, multivariate analysis showed VEGF content to be an independent predictor of OS (P = .0420; RR = 1.90) but not of RFS.

CONCLUSION: The results suggest that VEGF₁₆₅ content in tumor cytosols is a predictor of RFS and OS in primary NPBC. VEGF content might also predict outcome after adjuvant endocrine treatment, but further studies in a prospective setting with homologous treatments are required.

This article has been cited by other articles:

				K. Helczynska, A.-M. Larsson, L. Holmquist Mengelbier, E. Bridges, E. Fredlund, S. Borgquist, G. Landberg, S. Pahlman, and K. Jirstrom Hypoxia-Inducible Factor-2{alpha} Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer Cancer Res., November 15, 2008; 68(22): 9212 - 9220. [Abstract] [Full Text] [PDF]

				R. Aesoy, B. C. Sanchez, J. H. Norum, R. Lewensohn, K. Viktorsson, and B. Linderholm An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells Mol. Cancer Res., October 1, 2008; 6(10): 1630 - 1638. [Abstract] [Full Text] [PDF]

				Z. Qu, S. Van Ginkel, A. M. Roy, L. Westbrook, M. Nasrin, Y. Maxuitenko, A. R. Frost, D. Carey, W. Wang, R. Li, et al. Vascular Endothelial Growth Factor Reduces Tamoxifen Efficacy and Promotes Metastatic Colonization and Desmoplasia in Breast Tumors Cancer Res., August 1, 2008; 68(15): 6232 - 6240. [Abstract] [Full Text] [PDF]

				J. Gutierrez, G. E. Konecny, K. Hong, A. Burges, T. D. Henry, P. D. Lambiase, W. Lee Wong, and Y. G. Meng A New ELISA for Use in a 3-ELISA System to Assess Concentrations of VEGF Splice Variants and VEGF110 in Ovarian Cancer Tumors Clin. Chem., March 1, 2008; 54(3): 597 - 601. [Abstract] [Full Text] [PDF]

				M. Bergman Jungestrom, L. U. Thompson, and C. Dabrosin Flaxseed and Its Lignans Inhibit Estradiol-Induced Growth, Angiogenesis, and Secretion of Vascular Endothelial Growth Factor in Human Breast Cancer Xenografts In vivo Clin. Cancer Res., February 1, 2007; 13(3): 1061 - 1067. [Abstract] [Full Text] [PDF]

				S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF]

				S. B. Wedam, J. A. Low, S. X. Yang, C. K. Chow, P. Choyke, D. Danforth, S. M. Hewitt, A. Berman, S. M. Steinberg, D. J. Liewehr, et al. Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer J. Clin. Oncol., February 10, 2006; 24(5): 769 - 777. [Abstract] [Full Text] [PDF]

				S. D. Nathanson, R. Slater, D. DeBruyn, A. Kapke, and M. Linden HER-2/neu Expression in Primary Breast Cancer With Sentinel Lymph Node Metastasis Ann. Surg. Oncol., February 1, 2006; 13(2): 205 - 213. [Abstract] [Full Text] [PDF]

				L. Ryden, K. Jirstrom, P.-O. Bendahl, M. Ferno, B. Nordenskjold, O. Stal, S. Thorstenson, P.-E. Jonsson, and G. Landberg Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4695 - 4704. [Abstract] [Full Text] [PDF]

				H. Lu, X.-O. Shu, Y. Cui, N. Kataoka, W. Wen, Q. Cai, Z.-X. Ruan, Y.-T. Gao, and W. Zheng Association of Genetic Polymorphisms in the VEGF Gene with Breast Cancer Survival Cancer Res., June 15, 2005; 65(12): 5015 - 5019. [Abstract] [Full Text] [PDF]

				Q. Jin, K. Hemminki, K. Enquist, P. Lenner, E. Grzybowska, R. Klaes, R. Henriksson, B. Chen, J. Pamula, W. Pekala, et al. Vascular Endothelial Growth Factor Polymorphisms in Relation to Breast Cancer Development and Prognosis Clin. Cancer Res., May 15, 2005; 11(10): 3647 - 3653. [Abstract] [Full Text] [PDF]

				Y. Liu, R. T. Poon, Q. Li, T. W. Kok, C. Lau, and S. T. Fan Both Antiangiogenesis- and Angiogenesis-Independent Effects Are Responsible for Hepatocellular Carcinoma Growth Arrest by Tyrosine Kinase Inhibitor PTK787/ZK222584 Cancer Res., May 1, 2005; 65(9): 3691 - 3699. [Abstract] [Full Text] [PDF]

				A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]

				K. L. Blackwell, M. W. Dewhirst, V. Liotcheva, S. Snyder, G. Broadwater, R. Bentley, A. Lal, G. Riggins, S. Anderson, J. Vredenburgh, et al. HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors Clin. Cancer Res., June 15, 2004; 10(12): 4083 - 4088. [Abstract] [Full Text] [PDF]

				R. S. Herbst and A. B. Sandler Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab? Oncologist, June 1, 2004; 9(suppl_1): 19 - 26. [Abstract] [Full Text] [PDF]

				G. E. Konecny, Y. G. Meng, M. Untch, H.-J. Wang, I. Bauerfeind, M. Epstein, P. Stieber, J.-M. Vernes, J. Gutierrez, K. Hong, et al. Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients Clin. Cancer Res., March 1, 2004; 10(5): 1706 - 1716. [Abstract] [Full Text] [PDF]

				S. Leppa, T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa A High Serum Matrix Metalloproteinase-2 Level Is Associated with an Adverse Prognosis in Node-Positive Breast Carcinoma Clin. Cancer Res., February 1, 2004; 10(3): 1057 - 1063. [Abstract] [Full Text] [PDF]

				S. Garvin and C. Dabrosin Tamoxifen Inhibits Secretion of Vascular Endothelial Growth Factor in Breast Cancer in Vivo Cancer Res., December 15, 2003; 63(24): 8742 - 8748. [Abstract] [Full Text] [PDF]

				R. T.-P. Poon, C. P.-Y. Lau, J. W.-Y. Ho, W.-C. Yu, S.-T. Fan, and J. Wong Tissue Factor Expression Correlates with Tumor Angiogenesis and Invasiveness in Human Hepatocellular Carcinoma Clin. Cancer Res., November 1, 2003; 9(14): 5339 - 5345. [Abstract] [Full Text] [PDF]

				R. T.-P. Poon, C. P.-Y. Lau, S.-T. Cheung, W.-C. Yu, and S.-T. Fan Quantitative Correlation of Serum Levels and Tumor Expression of Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma Cancer Res., June 15, 2003; 63(12): 3121 - 3126. [Abstract] [Full Text] [PDF]

				C. Dabrosin Variability of Vascular Endothelial Growth Factor in Normal Human Breast Tissue in Vivo during the Menstrual Cycle J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2695 - 2698. [Abstract] [Full Text] [PDF]

				M. Colleoni, A. Rocca, M. T. Sandri, L. Zorzino, G. Masci, F. Nole, G. Peruzzotti, C. Robertson, L. Orlando, S. Cinieri, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann. Onc., January 19, 2002; 13(1): 73 - 80. [Abstract] [Full Text] [PDF]

				S. K. Chia, C. C. Wykoff, P. H. Watson, C. Han, R. D. Leek, J. Pastorek, K. C. Gatter, P. Ratcliffe, and A. L. Harris Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma J. Clin. Oncol., August 15, 2001; 19(16): 3660 - 3668. [Abstract] [Full Text] [PDF]

				J. A. Foekens, H. A. Peters, N. Grebenchtchikov, M. P. Look, M. E. Meijer-van Gelder, A. Geurts-Moespot, T. H. van der Kwast, C. G. J. Sweep, and J. G. M. Klijn High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer Cancer Res., July 1, 2001; 61(14): 5407 - 5414. [Abstract] [Full Text] [PDF]

				E. Laughner, P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1{alpha} (HIF-1{alpha}) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression Mol. Cell. Biol., June 15, 2001; 21(12): 3995 - 4004. [Abstract] [Full Text]

				B. K. Linderholm, T. Lindahl, L. Holmberg, S. Klaar, J. Lennerstrand, R. Henriksson, and J. Bergh The Expression of Vascular Endothelial Growth Factor Correlates with Mutant p53 and Poor Prognosis in Human Breast Cancer Cancer Res., March 1, 2001; 61(5): 2256 - 2260. [Abstract] [Full Text]

				R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]